Microbot Medical, Inc. (MBOT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MBOT SEC filings page.
This page shows Microbot Medical, Inc. (MBOT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The company is still pre-revenue, funded mainly by equity while development spending continues to consume operating cash.
Balance-sheet expansion was dramatic: assets rose from$6.0M in FY2024 to$81.5M in FY2025, a change operations did not generate. Financing provided$86.2M while debt-to-equity remained 0.1x, indicating that the expansion was primarily equity-funded rather than debt-driven.
Earnings quality is straightforward but still unfavorable: FY2025's net loss was
R&D and SG&A together consumed
Financial Health Signals
We are recalculating Microbot Medical, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Microbot Medical, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Microbot Medical, Inc. reported a net loss of $13.1M while operations used $13.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Microbot Medical, Inc. generated $241K in revenue in Q2 2026. Against the prior quarter it is up 129.5%.
Microbot Medical, Inc.'s EBITDA was -$6.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 66.3% from the same quarter a year earlier. Against the prior quarter it is down 43.3%.
Microbot Medical, Inc. reported -$5.6M in net income in Q2 2026. This represents a decrease of 60.8% from the same quarter a year earlier. Against the prior quarter it is down 53.3%.
Microbot Medical, Inc. earned -$0.08 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 60.0%.
Cash & Balance Sheet
Microbot Medical, Inc. recorded an outflow of $5.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 98.7% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.
Microbot Medical, Inc. held $3.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Microbot Medical, Inc.'s ROE was -8.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.2 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Microbot Medical, Inc. invested $1.9M in research and development in Q2 2026. This represents a decrease of 11.8% from the same quarter a year earlier. Against the prior quarter it is up 43.9%.
Microbot Medical, Inc. invested $142K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1477.8% from the same quarter a year earlier. Against the prior quarter it is up 31.5%.
Not reported for Q2 2026.
MBOT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $241K | $105K | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $884K | $103K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -$643K | $2K | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.9M-11.8% | $1.3M-11.4% | N/A | $1.2M-43.2% | $2.1M+49.0% | $1.5M+24.8% | N/A | $2.1M+27.8% |
| SG&A Expenses | $3.7M+128.5% | $3.0M+93.9% | N/A | $2.7M+116.9% | $1.6M+47.3% | $1.6M+28.6% | N/A | $1.2M+33.0% |
| Operating Income | -$6.2M-66.2% | -$4.3M-43.0% | N/A | -$3.9M-17.0% | -$3.7M-48.3% | -$3.0M-26.7% | N/A | -$3.3M-29.7% |
| EBITDA | -$6.2M-66.3% | -$4.3M-43.3% | N/A | -$3.9M-17.5% | -$3.7M-48.6% | -$3.0M-27.6% | N/A | -$3.3M-29.8% |
| Net Income | -$5.6M-60.8% | -$3.7M-41.1% | N/A | -$3.6M-11.3% | -$3.5M-42.0% | -$2.6M-9.7% | N/A | -$3.2M-31.4% |
| EPS (Basic) | -$0.08+20.0% | -$0.05+37.5% | -$0.04+80.0% | -$0.07+65.0% | -$0.10+41.2% | -$0.08+52.9% | -$0.20+23.1% | -$0.20+4.8% |
| EPS (Diluted) | -$0.08 | -$0.05 | -$0.04 | -$0.07 | -$0.10 | -$0.08 | -$0.20 | -$0.20+4.8% |
| Diluted Shares (Avg) | 67M | 67M | N/A | 48M | 36M | 31M | N/A | 16M+40.7% |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
MBOT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $73.4M+121.4% | $78.1M+152.7% | $81.5M+1252.1% | $81.8M+1469.9% | $33.1M+345.7% | $30.9M+319.3% | $6.0M-27.6% | $5.2M-41.4% |
| Current Assets | $72.2M+119.4% | $76.5M+149.6% | $79.8M+1271.7% | $80.8M+1517.3% | $32.9M+360.8% | $30.7M+337.9% | $5.8M-26.5% | $5.0M-40.6% |
| Cash & Equivalents | $3.2M-22.8% | $3.7M+13.7% | $3.9M+25.6% | $6.7M+1299.6% | $4.1M+65.6% | $3.2M+176.9% | $3.1M+26.2% | $479K-64.1% |
| Short-Term Investments | $64.2M+124.6% | $68.8M+153.4% | $74.7M+3069.8% | $73.5M+1803.4% | $28.6M+615.3% | $27.2M+423.9% | $2.4M-39.9% | $3.9M-43.4% |
| Inventory | $2.9M | $2.3M | $584K | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $176K | $105K | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.4M+60.0% | $4.0M+104.1% | $4.0M+59.5% | $3.5M+152.6% | $2.8M+101.2% | $1.9M+61.8% | $2.5M-34.6% | $1.4M-8.5% |
| Current Liabilities | $3.9M+42.6% | $3.4M+78.9% | $3.4M+39.1% | $2.9M+114.0% | $2.7M+103.4% | $1.9M+60.0% | $2.5M-35.0% | $1.4M-8.0% |
| Non-Current Liabilities | $550K+1070.2% | $574K+1095.8% | $569K+1287.8% | $602K+1975.9% | $47K+23.7% | $48K+182.4% | $41K+2.5% | $29K-25.6% |
| Total Equity | $68.9M+127.1% | $74.1M+156.0% | $77.6M+2097.0% | $78.2M+1954.2% | $30.4M+401.4% | $29.0M+369.5% | $3.5M-21.6% | $3.8M-48.2% |
| Retained Earnings | -$113.4M-16.8% | -$107.8M-15.2% | -$104.1M-14.5% | -$100.6M-14.9% | -$97.0M-15.1% | -$93.5M-14.3% | -$90.9M-14.4% | -$87.6M-14.7% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
MBOT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M-93.9% | -$5.1M-75.8% | -$3.8M-122.2% | -$3.8M-39.2% | -$2.6M-31.5% | -$2.9M-18.8% | -$1.7M+7.1% | -$2.8M-66.7% |
| Depreciation & Amortization | $15K+25.0% | $12K-20.0% | $10K-61.5% | $10K-56.5% | $12K-14.3% | $15K-46.4% | $26K-25.7% | $23K+15.0% |
| Stock-Based Compensation | $433K+82.7% | $222K-13.3% | N/A | N/A | $237K | $256K-43.5% | N/A | N/A |
| Capital Expenditures | $142K+1477.8% | $108K+730.8% | $25K+257.1% | $13K | $9K+125.0% | $13K-7.1% | $7K+40.0% | $0-100.0% |
| Free Cash Flow | -$5.1M-98.7% | -$5.2M-78.8% | -$3.8M-122.8% | -$3.9M-39.7% | -$2.6M-31.7% | -$2.9M-18.6% | -$1.7M+7.0% | -$2.8M-63.9% |
| Investing Cash Flow | $4.5M+441.6% | $5.0M+120.1% | -$1.5M-202.5% | -$44.7M-32037.1% | -$1.3M-210.4% | -$24.8M-1833.8% | $1.5M-49.4% | $140K+105.4% |
| Financing Cash Flow | N/A | N/A | $2.5M-11.5% | $51.2M+7984.7% | $4.8M+129.1% | $27.8M+1060.0% | $2.8M | $633K+493.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MBOT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -266.8% | 1.9% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -2567.6% | -4114.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -2334.9% | -3496.2% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -8.2%+3.4pp | -5.0%+4.0pp | N/A | -4.6%+79.9pp | -11.5%+29.2pp | -9.0%+29.5pp | N/A | -84.4%-51.2pp |
| Return on Assets | -7.7%+2.9pp | -4.7%+3.7pp | N/A | -4.4%+57.4pp | -10.6%+22.6pp | -8.4%+23.8pp | N/A | -61.7%-34.2pp |
| Current Ratio | 18.56+6.5x | 22.59+6.4x | 23.33+21.0x | 27.53+23.9x | 12.06+6.7x | 16.19+10.3x | 2.37+0.3x | 3.64-2.0x |
| Debt-to-Equity | 0.060.0x | 0.050.0x | 0.05-0.7x | 0.05-0.3x | 0.09-0.1x | 0.07-0.1x | 0.71-0.1x | 0.37+0.2x |
| Asset Turnover | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | -2129.1% | -4915.2% | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Microbot Medical, Inc. MBOT | FY2025 | N/A | -$13.1M | N/A | $71.9M | — |
| Anteris Technologies Global Corp. AVR | FY2025 | $1.9M | -$94.1M | N/A | $659.8M | 22/100 |
| KORU Medical Systems, Inc. KRMD | FY2025 | $41.1M | -$2.6M | -6.4% | $136.7M | 66/100 |
| Stereotaxis, Inc. STXS | FY2025 | $32.4M | -$21.6M | -66.8% | $111.2M | 43/100 |
| InfuSystem Holdings, Inc. INFU | FY2025 | $143.4M | $6.6M | 4.6% | $270.1M | 59/100 |
Where Microbot Medical, Inc. Ranks
Frequently Asked Questions
Is Microbot Medical, Inc. profitable?
No, Microbot Medical, Inc. (MBOT) reported a net income of -$13.1M in fiscal year 2025.
What is Microbot Medical, Inc.'s EBITDA?
Microbot Medical, Inc. (MBOT) had EBITDA of -$14.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Microbot Medical, Inc.'s return on equity (ROE)?
Microbot Medical, Inc. (MBOT) has a return on equity of -17.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Microbot Medical, Inc.'s free cash flow?
Microbot Medical, Inc. (MBOT) recorded an outflow of $13.1M in free cash flow during fiscal year 2025. This represents a -48.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Microbot Medical, Inc.'s operating cash flow?
Microbot Medical, Inc. (MBOT) recorded an outflow of $13.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Microbot Medical, Inc.'s total assets?
Microbot Medical, Inc. (MBOT) had $81.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Microbot Medical, Inc.'s capital expenditures?
Microbot Medical, Inc. (MBOT) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Microbot Medical, Inc. spend on research and development?
Microbot Medical, Inc. (MBOT) invested $6.3M in research and development during fiscal year 2025.
What is Microbot Medical, Inc.'s current ratio?
Microbot Medical, Inc. (MBOT) had a current ratio of 23.33 as of fiscal year 2025, which is generally considered healthy.
What is Microbot Medical, Inc.'s debt-to-equity ratio?
Microbot Medical, Inc. (MBOT) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Microbot Medical, Inc.'s return on assets (ROA)?
Microbot Medical, Inc. (MBOT) had a return on assets of -16.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Microbot Medical, Inc.'s P/E ratio?
Microbot Medical, Inc. (MBOT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $71.9M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Microbot Medical, Inc.'s price-to-sales ratio?
Microbot Medical, Inc. (MBOT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $71.9M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Microbot Medical, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Microbot Medical, Inc. (MBOT) held $78.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $13.0M over that year. Dividing the one by the other, the reported balance equals about 72 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Microbot Medical, Inc.'s Piotroski F-Score?
Microbot Medical, Inc. (MBOT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Microbot Medical, Inc.'s earnings high quality?
Microbot Medical, Inc. (MBOT) reported a net loss of $13.1M while operations used $13.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.